These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 35435646)

  • 1. D3 Receptors and Restless Legs Syndrome.
    Clemens S
    Curr Top Behav Neurosci; 2023; 60():229-249. PubMed ID: 35435646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. D3 and D1 receptors: The Yin and Yang in the treatment of restless legs syndrome with dopaminergics.
    Clemens S; Ghorayeb I
    Adv Pharmacol; 2019; 84():79-100. PubMed ID: 31229178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term treatment with dopamine D3 receptor agonists induces a behavioral switch that can be rescued by blocking the dopamine D1 receptor.
    Dinkins ML; Lallemand P; Clemens S
    Sleep Med; 2017 Dec; 40():47-52. PubMed ID: 29221778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. D3 receptor agonist efficacy in restless legs syndrome.
    Casoni F; Galbiati A; Ferini-Strambi L
    Adv Pharmacol; 2019; 84():21-35. PubMed ID: 31229173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential Dopamine D1 and D3 Receptor Modulation and Expression in the Spinal Cord of Two Mouse Models of Restless Legs Syndrome.
    Meneely S; Dinkins ML; Kassai M; Lyu S; Liu Y; Lin CT; Brewer K; Li Y; Clemens S
    Front Behav Neurosci; 2018; 12():199. PubMed ID: 30233336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Putative Animal Models of Restless Legs Syndrome: A Systematic Review and Evaluation of Their Face and Construct Validity.
    Silvani A; Ghorayeb I; Manconi M; Li Y; Clemens S
    Neurotherapeutics; 2023 Jan; 20(1):154-178. PubMed ID: 36536233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preferential D2 or preferential D3 dopamine agonists in restless legs syndrome.
    Manconi M; Ferri R; Zucconi M; Clemens S; Giarolli L; Bottasini V; Ferini-Strambi L
    Neurology; 2011 Jul; 77(2):110-7. PubMed ID: 21715702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Opposing aging-related shift of excitatory dopamine D1 and inhibitory D3 receptor protein expression in striatum and spinal cord.
    Keeler BE; Lallemand P; Patel MM; de Castro Brás LE; Clemens S
    J Neurophysiol; 2016 Jan; 115(1):363-9. PubMed ID: 26561599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, double-blind, placebo-controlled, short-term trial of ropinirole in restless legs syndrome.
    Bliwise DL; Freeman A; Ingram CD; Rye DB; Chakravorty S; Watts RL
    Sleep Med; 2005 Mar; 6(2):141-7. PubMed ID: 15716217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Connectome and molecular pharmacological differences in the dopaminergic system in restless legs syndrome (RLS): plastic changes and neuroadaptations that may contribute to augmentation.
    Earley CJ; Uhl GR; Clemens S; Ferré S
    Sleep Med; 2017 Mar; 31():71-77. PubMed ID: 27539027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pathophysiology of restless legs syndrome].
    Miyamoto M; Miyamoto T; Iwanami M; Suzuki K; Hirata K
    Brain Nerve; 2009 May; 61(5):523-32. PubMed ID: 19514512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of dopamine receptor agonists in the treatment of restless legs syndrome.
    Happe S; Trenkwalder C
    CNS Drugs; 2004; 18(1):27-36. PubMed ID: 14731057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biased G Protein-Independent Signaling of Dopamine D
    Guitart X; Moreno E; Rea W; Sánchez-Soto M; Cai NS; Quiroz C; Kumar V; Bourque L; Cortés A; Canela EI; Bishop C; Newman AH; Casadó V; Ferré S
    Mol Neurobiol; 2019 Oct; 56(10):6756-6769. PubMed ID: 30919214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe restless legs syndrome in a family with Alport syndrome.
    Sparasci D; Rossinelli A; Ferri R; Cippà P; Rinaldi A; Manconi M
    BMC Nephrol; 2021 Jul; 22(1):249. PubMed ID: 34225668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Less is more: pathophysiology of dopaminergic-therapy-related augmentation in restless legs syndrome.
    Paulus W; Trenkwalder C
    Lancet Neurol; 2006 Oct; 5(10):878-86. PubMed ID: 16987735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopamine and the spinal cord in restless legs syndrome: does spinal cord physiology reveal a basis for augmentation?
    Paulus W; Schomburg ED
    Sleep Med Rev; 2006 Jun; 10(3):185-96. PubMed ID: 16762808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From bench to bedside: An overview of rotigotine for the treatment of restless legs syndrome.
    Bogan RK
    Clin Ther; 2014 Mar; 36(3):436-55. PubMed ID: 24636821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Akathisia and Restless Legs Syndrome: Solving the Dopaminergic Paradox.
    Ferré S; Guitart X; Quiroz C; Rea W; García-Malo C; Garcia-Borreguero D; Allen RP; Earley CJ
    Sleep Med Clin; 2021 Jun; 16(2):249-267. PubMed ID: 33985651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopamine D3 receptor specifically modulates motor and sensory symptoms in iron-deficient mice.
    Dowling P; Klinker F; Stadelmann C; Hasan K; Paulus W; Liebetanz D
    J Neurosci; 2011 Jan; 31(1):70-7. PubMed ID: 21209191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conversion of the modulatory actions of dopamine on spinal reflexes from depression to facilitation in D3 receptor knock-out mice.
    Clemens S; Hochman S
    J Neurosci; 2004 Dec; 24(50):11337-45. PubMed ID: 15601940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.